Form DEF 14A - Other definitive proxy statements
SEC Accession No. 0001193125-26-171800
Filing Date
2026-04-23
Accepted
2026-04-23 07:01:02
Documents
18
Period of Report
2026-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A amlx-20260422.htm   iXBRL DEF 14A 1655560
2 GRAPHIC img176765742_0.jpg GRAPHIC 103455
3 GRAPHIC img176765742_1.jpg GRAPHIC 103455
4 GRAPHIC img176765742_2.gif GRAPHIC 97611
5 GRAPHIC img176765742_3.gif GRAPHIC 109522
6 GRAPHIC img176765742_4.jpg GRAPHIC 240705
7 GRAPHIC img176765742_5.jpg GRAPHIC 256665
  Complete submission text file 0001193125-26-171800.txt   4959318

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20260422.xsd EX-101.SCH 42908
21 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20260422_htm.xml XML 379223
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142 617-682-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41199 | Film No.: 26885485
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)